UNICHEM LABORATORIES LTD.

4th November 2026

Department of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Script Code: 506690

National Stock Exchange of India,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051

Symbol: UNICHEMLAB

Dear Sir/Madam,

Sub: Outcome of Board Meeting

We would like to inform you that the Board of Directors at its Meeting held today, i.e. Wednesday, 4th November 2026 approved Unaudited Financial Statements (Consolidated & Standalone) for the second quarter and half year ended 30th September 2026.

Enclosed herewith are the Unaudited Financial Statements (Consolidated & Standalone) for the second quarter and half year ended 30th September 2026 along with Limited Review report by Auditors.

The Board meeting commenced at 11:30 a.m. and concluded at 01:45 p.m. The same will also be made available on the Company's website www.unichemlabs.com as well as on www.bseindia.com and www.nseindia.com.

Kindly take the same on your records.5

Thanking you,

FOR UNICHEM LABORATORIES LIMITED

Pradeep Gautam Bhandari
Date: 2026.11.04 13:49:35 +05'30'

UNICHEM LABORATORIES LTD. MUMBAI 400 067.

PRADEEP BHANDARI
Head – Legal & Company Secretary

Encl.: a/a

UNICHEM LABORATORIES LIMITED

Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, Maharashtra, India.
Tel: +91(22)66474100. Website: www.unichemlabs.com. CIN: L99999MH1962PLC012451

Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year ended 30th September 2026

₹ Crores

	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	640.22	632.62	578.96	1,272.84	1,105.56	2,201.85
II	Other income	15.37	15.61	20.97	30.98	27.79	63.06
III	**Total income (I+II)**	**655.59**	**648.23**	**599.93**	**1,303.82**	**1,133.35**	**2,264.91**
IV	**EXPENSES**						
	Cost of materials consumed	255.11	190.02	193.06	445.13	410.54	768.83
	Purchase of stock-in-trade	68.17	67.25	39.76	135.42	90.77	231.51
	Changes in inventories of stock-in-trade, finished goods and work-in-progress	(52.79)	31.32	37.56	(21.47)	14.12	20.21
	Employee benefits expense (Refer note 6)	105.57	103.31	100.13	208.88	207.55	396.63
	Finance costs	7.71	6.62	8.24	14.33	14.78	31.59
	Depreciation and amortization expenses	30.49	29.94	31.47	60.43	63.26	125.12
	Other expenses	189.70	170.78	142.27	360.48	293.91	600.50
	Total expenses (IV)	**603.96**	**599.24**	**552.49**	**1,203.20**	**1,094.93**	**2,174.39**
V	Share of profit / (loss) in associate (net of tax)	-	-	-	-	-	-
VI	**Profit / (Loss) before exceptional items and tax (III- IV+V)**	**51.63**	**48.99**	**47.44**	**100.62**	**38.42**	**90.52**
VII	Exceptional items - expenses/(income) (Refer note 5)	24.26	-	58.26	24.26	58.26	(201.86)
VIII	**Profit / (Loss) before tax (VI-VII)**	**27.37**	**48.99**	**(10.82)**	**76.36**	**(19.84)**	**292.38**
IX	Tax expense (Refer note 4)						
	(1) Current tax	1.76	0.72	0.98	2.48	1.94	3.57
	(2) Deferred tax charge / (credit)	3.39	6.80	0.09	10.19	0.14	35.53
	(3) Short / (excess) provision for tax (earlier years)	-	-	-	-	0.44	0.44
		5.15	**7.52**	**1.07**	**12.67**	**2.52**	**39.54**
X	**Profit / (Loss) for the period after tax (VIII-IX)**	**22.22**	**41.47**	**(11.89)**	**63.69**	**(22.36)**	**252.84**
XI	Other Comprehensive Income / (Loss)						
	A. (i) Items that will not be reclassified subsequently to profit or loss						
	- Remeasurement of the net defined benefit plan	3.37	0.28	1.14	3.65	6.01	10.15
	(ii) Income tax (expense) / credit relating to items that will not be reclassified to profit or loss						
	- Remeasurement of the net defined benefit plan	(0.85)	(0.07)	-	(0.92)	-	(2.55)
	B. (i) Items that will be reclassified to profit or loss (Foreign currency translation difference)						
	-Foreign currency translation difference	0.68	(3.27)	0.71	(2.59)	(1.11)	4.39
	(ii) Income tax relating to items that will be reclassified to profit or loss						
	-Foreign currency translation difference	-	-	-	-	-	-
	Total of Other Comprehensive Income / (Loss)	**3.20**	**(3.06)**	**1.85**	**0.14**	**4.90**	**11.99**
XII	**Total Comprehensive Income/(loss) for the period (X+XI)**	**25.42**	**38.41**	**(10.04)**	**63.83**	**(17.46)**	**264.83**
XIII	Paid-up equity share capital (Face value of ₹ 2/- per share)	14.08	14.08	14.08	14.08	14.08	14.08
XIV	Other Equity (Reserves excluding revaluation reserve)						2,688.66
XV	Earnings per equity share (Face value of ₹ 2/- per share) (not annualized)						
	(1) Basic	3.16	5.89	(1.69)	9.05	(3.18)	35.91
	(2) Diluted	3.14	5.89	(1.69)	9.03	(3.18)	35.85

UNICHEM

UNICHEM LABORATORIES LIMITED

Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, Maharashtra, India.
Tel: +91(22)66474100. Website: www.unichemlabs.com. CIN: L99999MH1962PLC012451

Statement of Consolidated Assets and Liabilities

₹ Crores

Particulars	As at 30th September, 2026	As at 31st March, 2026
	Unaudited	Audited
I. ASSETS		
Non-current assets		
(a) Property, plant and equipment	1,117.65	1,135.90
(b) Right-of-use assets	45.09	67.80
(c) Capital work-in-progress	126.40	100.14
(d) Goodwill	1.55	1.55
(e) Other intangible assets	5.28	7.33
(f) Financial assets		
(i) Investments	0.02	0.02
(ii) Loans	0.10	0.11
(iii) Other financial assets	10.14	8.59
(g) Deferred tax assets (net)	32.90	30.56
(h) Other non-current assets	203.02	184.85
	1,542.15	**1,536.85**
Current assets		
(a) Inventories	1,083.46	974.97
(b) Financial Assets		
(i) Trade receivables	985.83	828.58
(ii) Cash and bank balances		
Cash & cash equivalents	157.01	289.48
Other bank balances	3.36	5.22
(iii) Loans	0.06	0.06
(iv) Other financial assets	19.98	4.42
(c) Other current assets	112.48	94.61
	2,362.18	**2,197.34**
Non-Current Assets held for sale	**3.22**	**3.25**
TOTAL ASSETS	**3,907.55**	**3,737.44**
II. EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	14.08	14.08
(b) Other equity	2,767.35	2,703.36
	2,781.43	**2,717.44**
Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	32.35	39.12
(ii) Lease liabilities	18.21	26.00
(b) Provisions	21.72	28.64
(c) Deferred tax liabilities (net)	52.98	39.88
(d) Other non-current liabilities	0.19	0.42
	125.45	**134.06**
Current liabilities		
(a) Financial liabilities		
(i) Borrowings	442.21	429.66
(ii) Lease liabilities	5.49	5.37
(iii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	20.93	14.98
Total outstanding dues of creditors other than micro enterprises and small enterprises	432.79	341.65
(iv) Other financial liabilities	36.93	59.66
(b) Other current liabilities	32.53	29.92
(c) Provisions	29.61	4.70
(d) Current tax liabilities (net)	0.18	-
	1,000.67	**885.94**
TOTAL EQUITY AND LIABILITIES	**3,907.55**	**3,737.44**

UNICHEM

UNICHEM LABORATORIES LIMITED

Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, Maharashtra, India.
Tel: +91(22)66474100. Website: www.unichemlabs.com. CIN: L99999MH1962PLC012451

Statement of Consolidated Cash Flows

₹ Crores

Particulars	Six months ended 30th September, 2026 (Unaudited)		Six months ended 30th September, 2025 (Unaudited)	
A.Cash Flow from Operating Activities				
Net Profit / (Loss) before tax		**76.36**		**(19.84)**
Adjustments:				
Depreciation / amortisation expense	60.43		63.26	
Loss / (profit) on sale / surrender /discard of property, plant and equipment (net)	(3.75)		0.16	
Impairmement loss on property, plant and equipment	-		3.12	
Unrealised exchange difference (gain) / loss (net)	6.84		0.69	
Gain on sale of subsidiary	-		(1.99)	
Rent income *	-		(0.03)	
Finance cost	14.13		14.78	
Provision for doubtful debts, loans, advances & deposits (net)	1.68		(0.43)	
Share-based payment to employees	0.16		0.50	
Fair value (gain)/loss on investments (net)	1.53		(0.69)	
Bad debts written off	0.25		-	
Interest income	(0.50)		(3.26)	
Sundry balance written off / (written back)	(1.20)		-	
Provision for European commission fine	-		58.26	
Provision for Claims	24.26		-	
Dividend income *	-		-	
		103.83		**134.37**
Operating Profit / (Loss) before Working Capital changes		**180.19**		**114.53**
Working Capital Adjustments:				
Trade receivables & other assets	(229.48)		44.23	
Inventories	(108.49)		10.84	
Trade payables & other liabilities	92.98		(68.24)	
		(244.99)		**(13.17)**
Cash generated from / (used in) operations		**(64.80)**		**101.36**
Direct taxes refund received / (payment made)		(3.27)		(1.92)
Net Cash Flow from / (used in) Operating Activities [A]		**(68.07)**		**99.44**
B. Cash Flow from Investing Activities				
Purchase of property, plant and equipment including capital work-in-progress		(55.17)		(58.61)
Proceeds from sale of property, plant and equipment and intangible assets		0.26		0.00
Proceeds from sale of investment in subsidiary		-		4.00
Rent received *		-		0.03
(Increase) / decrease in escrow bank accounts & fixed deposits		1.86		12.61
Interest received		1.38		4.38
Dividend received *		-		-
Net Cash Flow from / (used in) Investing Activities [B]		**(51.67)**		**(37.59)**
C. Cash Flow from Financing Activities				
Increase / (decrease) in working capital borrowings (net)		12.40		54.51
Payments of lease liabilities		(3.22)		(3.09)
Repayments of term loan to bank		(6.29)		(12.84)
Finance cost paid		(13.93)		(12.36)
Dividend paid (transferred to Investor Education and Protection Fund)		(0.16)		(0.31)
Net Cash Flow from / (used in) Financing Activities [C]		**(11.20)**		**25.91**
Net (Decrease) / Increase in Cash and Cash Equivalents [A+B+C]		**(130.94)**		**87.76**
Cash and Cash Equivalents at the beginning of the period		**289.48**		**89.58**
Effect of fair value gain / (loss) on liquid mutual funds		(1.53)		0.69
Cash and Cash Equivalents at the end of the period		**157.01**		**178.03**

* Amount less than ₹ 0.5 lakhs

UNICHEM

UNICHEM LABORATORIES LIMITED

Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, Maharashtra, India.
Tel: +91(22)66474100. Website: www.unichemlabs.com. CIN: L99999MH1962PLC012451

Notes:

1 The above unaudited consolidated financial results ("the Statement") for the quarter and half year ended 30th September, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 4th November, 2026. The statutory auditors have expressed an unmodified audit conclusion on these consolidated financial results for the quarter and half year ended 30th September, 2026.

2 The above Statement has been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI") and the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013.

3 Operating Segment: The Company has a single reportable segment i.e. 'Pharmaceuticals'.

4 In respect of the Company, there is no current tax charge for the reporting quarter, considering the set-off of unabsorbed tax depreciation and business loss from earlier periods. For the previous year ended 31st March 2026, there was no current tax charge, considering set-off of unabsorbed tax depreciation, capital loss and business loss. Further, deferred tax liability (net) has been recorded. In respect of subsidiaries, income tax is recognised as per applicable tax laws.

5 Exceptional Items comprise of the following:

₹ Crores

Particulars	Quarter ended			Half year ended		Year ended
	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
Employee benefit expense (refer note 6 below)	-	-	-	-	-	15.40
Net (gain) / loss on disposal of land & building [erstwhile Registered office]	-	-	-	-	-	(275.52)
Interest on European commission fine (refer note 7 below)	-	-	58.26	-	58.26	58.26
Provision for Claims (refer note 8 below)	24.26	-	-	24.26	-	-
Total Exceptional Items – expenses / (income)	**24.26**	**-**	**58.26**	**24.26**	**58.26**	**(201.86)**

6 The New Labour Codes had resulted in a one-time increase in provision for employee benefits on account of recognition of past service costs of ₹ 15.40 crores which is disclosed as Exceptional Items during the year ended 31st March, 2026. The Company continues to monitor the developments pertaining to the New Labour Codes.

7 The Company and its subsidiary Niche Generics Limited ("Niche") had received a demand order dated 17th September 2025 from the European Commission (EU) for payment of fine and interest aggregating to Euro 19.55 million and the same was fully settled by the Company on 28th October 2025 after adjusting the payments of Euro 2.79 million already made by Niche in instalments to EU. In regard to above, the Company had fully recognised a provision in books towards payment of fine amounting to Euro 13.96 million towards EU fine during year ended 31st March 2024 and the balance amount representing the interest was recorded in year ended 31st March 2026 under exceptional items.

8 Laboratories Servier had filed a claim against the Company and its subsidiary Niche Generics Limited ("Niche"), amongst others, seeking a contribution towards damages claimed by UK Health Authorities in relation to Perindopril proceedings in the UK. In view of the significant legal costs involved, Niche Generics Limited intends to resolve the matter at the earliest opportunity and by compromise if possible. Accordingly, a provision of £1.9 million (equivalent to ₹ 24.26 crores) has been recognised as an expense in the books of Niche and for the purpose of consolidated financial results of the Company it is grouped under exceptional items for the quarter and half year ended 30th September 2026.

SIGNED FOR IDENTIFICATION
BHAVIN SURENDRA KAPADIA
Digitally signed by BHAVIN SURENDRA KAPADIA
Date: 2026.11.04 13:12:59 +05'30'
N. A. SHAH ASSOCIATES LLP
MUMBAI

Place: Mumbai
Date: 4th November, 2026

By Order of the Board
For Unichem Laboratories Limited

Pabitrakumar Kalipada Bhattacharyya
Date: 2026.11.04 12:57:17 +05'30'

UNICHEM LABORATORIES LTD. MUMBAI 400 067

Pabitrakumar Kalipada Bhattacharyya
Managing Director and Chief Executive Officer
DIN: 07131152

UNICHEM

Independent Auditor's Review Report on Quarterly and Half yearly Consolidated Unaudited Financial Results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors
Unichem Laboratories Limited

1. We have reviewed the accompanying statement of consolidated unaudited financial results of **Unichem Laboratories Limited** ("the Holding Company"), comprising its subsidiaries (the Holding and its subsidiaries collectively referred to as "the Group") for the quarter and half year ended 30th September 2026 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

Management's responsibility

2. The Statement is the responsibility of the Holding Company's Management and has been approved by the Holding Company's Board of Directors. The Statement has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

Auditor's responsibility

3. Our responsibility is to issue a report on this Statement based on our review.

   We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Independent Auditor's Review Report on Quarterly and Half yearly Consolidated Unaudited Financial Results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (continued)

4. These consolidated unaudited financial results include results of the following subsidiaries:

    1) Niche Generics Limited, United Kingdom
    2) Unichem Pharmaceuticals (USA), Inc., USA
    3) Unichem SA (Pty) Limited, South Africa
    4) Unichem Farmaceutica Do Brasil Ltda, Brazil
    5) Unichem (China) Pvt. Ltd.

Basis for conclusion

5. Based on our review conducted and procedures performed as stated in above auditor's responsibility paragraph and based on the consideration of the review reports of the subsidiaries reviewed by another auditor and management certified accounts furnished to us, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other matters

6. We did not review the interim financial statements of the subsidiary at USA and Niche, whose interim financial statements reflect total assets of Rs. 1,251.90 crores as at 30th September 2026, total revenue (including other income) of Rs. 478.38 crores and Rs. 948.66 crores, total net profit after tax and total comprehensive income of Rs. 0.40 crores and Rs. 12.79 crores for the quarter and half year ended 30th September 2026 respectively and net cash inflow/ (outflow) of Rs. 17.20 crores for the half year ended 30th September 2026 as considered in the unaudited consolidated financial results. These financial results have been reviewed by other auditors whose report has been furnished to us by the Management and our conclusion on the unaudited consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of this subsidiary and our report in terms of the Listing Regulations (as amended), in so far as it relates to aforesaid subsidiary located outside India is based on the report of other auditor and the procedures performed by us as stated in paragraph 3 above.

7. We also did not review the interim financial information of other subsidiaries as mentioned in paragraph 4 above, whose interim financial statements reflect total assets of Rs. 36.58 crores as at 30th September 2026, total revenue (including other income) of Rs. 25.04 crores and Rs. 48.63 crores, total net profit / (loss) after tax and total comprehensive income of Rs. 1.17 crores and Rs. 1.09 crores for the quarter and half year ended 30th September 2026 respectively and net cash inflow/ (outflow) of Rs. 0.96 crores for the half year ended 30th September 2026, as considered in the unaudited consolidated financial results. These financial information are not subject to limited review by their auditors and have been furnished to us by the Management and our conclusion on the consolidated unaudited financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is solely based on the information provided by the Management. According to the information and explanations given to us by the Management, these financial information are not material to the Group.

Independent Auditor's Review Report on Quarterly and and Half yearly Consolidated Unaudited Financial Results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (continued)

8. In case of associate, the carrying value of investment had been fully impaired. Further, financial information of associate is not available for the quarter and half year ended 30th September 2026. In view of the above and in our opinion and according to the information and explanations given to us by the Management, this financial information is not material to the Group.

   Our conclusion on the Statement is not modified in respect of the matters stated in paragraph 6, 7 and 8 above.

For N. A. Shah Associates LLP
Chartered Accountants
Firm's Registration No.: 116560W / W100149

BHAVIN SURENDRA KAPADIA
Digitally signed by BHAVIN SURENDRA KAPADIA
Date: 2026.11.04 13:15:30 +05'30'

Bhavin Kapadia
Partner
Membership No.: 118991
UDIN: 26118991CBPFGX2994

Place: Mumbai
Date: 04th November 2026

UNICHEM LABORATORIES LIMITED

Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, Maharashtra, India.
Tel: +91(22)66474100. Website: www.unichemlabs.com. CIN: L99999MH1962PLC012451

Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended 30th September 2026

₹ Crores

	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	401.90	366.27	356.90	768.17	741.15	1,412.29
II	Other income	16.85	16.72	21.40	33.57	25.65	62.90
III	**Total income (I+II)**	**418.75**	**382.99**	**378.30**	**801.74**	**766.80**	**1,475.19**
IV	**EXPENSES**						
	Cost of materials consumed	243.77	168.80	165.31	412.57	369.19	671.59
	Purchase of stock-in-trade	0.50	0.17	0.47	0.67	0.59	1.05
	Changes in inventories of stock-in-trade, finished goods and work-in-progress	(67.42)	(14.53)	6.91	(81.95)	(15.17)	(7.28)
	Employee benefits expense (Refer note 5)	75.95	73.50	72.88	149.45	145.74	277.22
	Finance costs	1.77	1.29	3.68	3.06	5.61	11.80
	Depreciation and amortization expenses	28.98	28.69	30.11	57.67	60.04	119.03
	Other expenses	133.17	117.69	103.63	250.86	207.36	419.35
	Total expenses (IV)	**416.72**	**375.61**	**382.99**	**792.33**	**773.36**	**1,492.76**
V	**Profit / (Loss) before exceptional items and tax (III-IV)**	**2.03**	**7.38**	**(4.69)**	**9.41**	**(6.56)**	**(17.57)**
VI	Exceptional items - expenses/(income) (Refer note 4)	-	-	33.14	-	33.14	(226.98)
VII	**Profit / (Loss) before tax (V-VI)**	**2.03**	**7.38**	**(37.83)**	**9.41**	**(39.70)**	**209.41**
VIII	Tax expense (Refer note 7)						
	(1) Current tax	-	-	-	-	-	-
	(2) Deferred tax charge / (credit)	0.54	1.85	2.10	2.39	1.64	50.03
	(3) Short / (excess) provision for tax (earlier years)	-	-	-	-	0.44	0.44
		0.54	**1.85**	**2.10**	**2.39**	**2.08**	**50.47**
IX	**Profit / (Loss) for the period after tax (VII-VIII)**	**1.49**	**5.53**	**(39.93)**	**7.02**	**(41.78)**	**158.94**
X	Other Comprehensive Income / (Loss)						
	A. (i) Items that will not be reclassified subsequently to profit or loss						
	- Remeasurement of the net defined benefit plan	3.37	0.28	1.14	3.65	6.01	10.15
	(ii) Income tax (expense) / credit relating to items that will not be reclassified to profit or loss						
	- Remeasurement of the net defined benefit plan	(0.85)	(0.07)	(0.32)	(0.92)	(1.51)	(2.55)
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total of Other Comprehensive Income / (Loss)	**2.52**	**0.21**	**0.82**	**2.73**	**4.50**	**7.60**
XI	**Total Comprehensive Income/(loss) for the period (IX+X)**	**4.01**	**5.74**	**(39.11)**	**9.75**	**(37.28)**	**166.54**
XII	Paid-up equity share capital (Face value of ₹ 2/- per share)	14.08	14.08	14.08	14.08	14.08	14.08
XIII	Other Equity (Reserves excluding revaluation reserve)						2,598.32
XIV	Earnings per equity share (Face value of ₹ 2/- per share) (not annualized)						
	(1) Basic	0.21	0.79	(5.67)	1.00	(5.93)	22.57
	(2) Diluted	0.21	0.79	(5.67)	1.00	(5.93)	22.53

UNICHEM

UNICHEM LABORATORIES LIMITED

Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, Maharashtra, India.
Tel: +91(22)66474100. Website: www.unichemlabs.com. CIN: L99999MH1962PLC012451

Statement of Standalone Assets and Liabilities

₹Crores

Particulars	As at 30th September, 2026	As at 31st March, 2026
	Unaudited	Audited
I. ASSETS		
Non-current assets		
(a) Property, plant and equipment	1,115.86	1,133.81
(b) Right-of-use assets	27.58	48.34
(c) Capital work-in-progress	123.09	100.50
(d) Other Intangible assets	5.28	7.33
(e) Financial assets		
(i) Investments	48.41	47.49
(ii) Loans	28.85	28.56
(iii) Other financial assets	7.29	6.72
(f) Other non-current assets	201.75	182.80
	1,558.11	**1,555.55**
Current assets		
(a) Inventories	763.42	592.48
(b) Financial assets		
(i) Trade receivables	629.60	582.94
(ii) Cash and bank balances		
Cash & cash equivalents	101.46	252.67
Other bank balances	3.36	5.22
(iii) Loans	9.64	9.54
(iv) Other financial assets	20.37	4.42
(c) Other current assets	100.99	86.38
	1,628.84	**1,533.65**
Non-Current Assets held for sale	**3.22**	**3.25**
TOTAL ASSETS	**3,190.17**	**3,092.45**
II. EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	14.08	14.08
(b) Other equity	2,622.93	2,613.02
	2,637.01	**2,627.10**
Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	32.35	39.12
(ii) Lease liabilities	3.93	9.76
(b) Provisions	21.72	28.64
(c) Deferred tax liabilities (net)	75.76	72.45
(d) Other non-current liabilities	0.19	0.42
	133.95	**150.39**
Current liabilities		
(a) Financial liabilities		
(i) Borrowings	14.37	14.22
(ii) Lease liabilities	1.10	0.98
(iii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	20.93	14.98
Total outstanding dues of creditors other than micro enterprises and small enterprises	323.98	210.39
(iv) Other financial liabilities	29.19	45.48
(b) Other current liabilities	24.22	24.21
(c) Provisions	5.42	4.70
	419.21	**314.96**
TOTAL EQUITY AND LIABILITIES	**3,190.17**	**3,092.45**

UNICHEM LABORATORIES LIMITED

Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, Maharashtra, India.

Tel: +91(22)66474100. Website: www.unichemlabs.com. CIN: L99999MH1962PLC012451

Statement of Standalone Cash Flows

₹Crores

Particulars	Six months ended 30th September, 2026 (Unaudited)		Six months ended 30th September, 2025 (Unaudited)	
A.Cash Flow from Operating Activities				
Net Profit / (Loss) before tax		**9.41**		**(39.70)**
Adjustments:				
Depreciation / amortisation expense	57.67		60.04	
Loss / (profit) on sale / discard of property, plant and equipment (net)	(3.75)		0.17	
Unrealised exchange difference (gain) / loss (net)	4.42		2.99	
Rent income *	-		(0.03)	
Guarantee commission income	(2.49)		(1.27)	
Finance cost	2.86		5.61	
Provision for doubtful debts, loans, advances & deposits (net)	1.12		(0.43)	
Fair value (gain)/loss on investments (net)	1.53		(0.69)	
Bad debts written off	-		-	
Interest income	(1.35)		(4.30)	
Sundry balance written off / (written back)	(1.20)		-	
Provision for European commission fine	-		33.14	
Dividend income *	-		-	
		58.81		**95.23**
Operating Profit / (Loss) before Working Capital changes		**68.22**		**55.53**
Working Capital Adjustments:				
Trade receivables & other assets	(109.74)		143.69	
Inventories	(170.94)		(21.23)	
Trade payables & other liabilities	120.02		(5.53)	
		(160.66)		**116.93**
Cash generated from / (used in) operations		**(92.44)**		**172.46**
Direct taxes refund received / (payment made)		(0.97)		3.90
Net Cash Flow from / (used in) Operating Activities [A]		**(93.41)**		**176.36**
B. Cash Flow from Investing Activities				
Purchase of property, plant and equipment including capital work-in-progress		(51.61)		(59.20)
Proceeds from sale of investment in subsidiary		-		4.00
Proceeds from sale of property, plant and equipment and intangible assets		0.26		-
Investments made				
- in subsidiaries (at cost)		(0.76)		(1.05)
Guarantee commission income realised		2.37		0.06
Rent received *		-		0.03
(Increase) / decrease in escrow bank accounts & fixed deposits		1.86		12.61
Interest received		1.74		5.42
Dividend received *		-		-
Net Cash Flow from / (used in) Investing Activities [B]		**(46.14)**		**(38.13)**
C. Cash Flow from Financing Activities				
Increase / (decrease) in working capital borrowings (net)		-		(21.19)
Repayments of term loan to bank		(6.29)		(12.84)
Payments of lease liabilities		(0.97)		(0.97)
Finance cost paid		(2.71)		(3.22)
Dividend paid (transferred to Investor Education and Protection Fund)		(0.16)		(0.30)
Net Cash Flow from / (used in) Financing Activities [C]		**(10.13)**		**(38.52)**
Net (Decrease) / Increase in Cash and Cash Equivalents [A+B+C]		**(149.68)**		**99.71**
Cash and Cash Equivalents at the beginning of the period		**252.67**		**60.58**
Effect of fair value gain / (loss) on liquid mutual funds		(1.53)		0.69
Cash and Cash Equivalents at the end of the period		**101.46**		**160.98**

* Amount less than ₹ 0.5 lakhs

UNICHEM

UNICHEM LABORATORIES LIMITED

Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, Maharashtra, India.
Tel: +91(22)66474100. Website: www.unichemlabs.com. CIN: L99999MH1962PLC012451

Notes:

1 The above unaudited standalone financial results ("the Statement") for the quarter and half year ended 30th September, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 4th November, 2026. The statutory auditors have expressed an unmodified audit conclusion on these standalone financial results for the quarter and half year ended 30th September, 2026.

2 The above Statement has been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI") and the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013.

3 Operating Segment: The Company has a single reportable segment i.e. 'Pharmaceuticals'.

4 Exceptional Items comprise of the following:

₹ Crores

Particulars	Quarter ended			Half year ended		Year ended
	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
Employee benefit expense (refer note 5 below)	-	-	-	-	-	15.40
Net (gain) / loss on disposal of land & building [erstwhile Registered office]	-	-	-	-	-	(275.52)
Interest on European commission fine (refer note 6 below)	-	-	58.26	-	58.26	58.26
Reversal of provision for European commission fine (net) (refer note 6 below)	-	-	(25.12)	-	(25.12)	(25.12)
Total Exceptional Items – expenses / (income)	-	-	**33.14**	-	**33.14**	**(226.98)**

5 The New Labour Codes had resulted in a one-time increase in provision for employee benefits on account of recognition of past service costs of ₹ 15.40 crores which is disclosed as Exceptional Items during the year ended 31st March, 2026. The Company continues to monitor the developments pertaining to the New Labour Codes.

6 The Company and its subsidiary Niche Generics Limited ("Niche") had received a demand order dated 17th September 2025 from the European Commission (EU) for payment of fine and interest aggregating to Euro 19.55 million and the same was fully settled by the Company on 28th October 2025 after adjusting the payments of Euro 2.79 million already made by Niche in instalments to EU. In regard to above, the Company had fully recognised a provision in books towards payment of fine amounting to Euro 13.96 million towards EU fine during year ended 31st March 2024 and the balance amount representing the interest was recorded in year ended 31st March 2026 under exceptional items.

7 There is no current tax charge for the reporting quarter, considering the set-off of unabsorbed tax depreciation and business loss. For the previous year ended 31st March 2026, there was no current tax charge, considering set-off of unabsorbed tax depreciation, capital loss and business loss. Further, deferred tax liability (net) has been recorded.

8 During the half year ended 30th September 2026, the Company has invested USD 80,000 (equivalent to ₹ 0.76 crores) towards redeemable preference shares in its wholly owned subsidiary - "Unichem (China) Pvt Ltd."

SIGNED FOR IDENTIFICATION
BHAVIN SURENDRA KAPADIA
Digitally signed by BHAVIN SURENDRA KAPADIA
Date: 2026.11.04 13:13:38 +05'30'
N. A. SHAH ASSOCIATES LLP
MUMBAI

Place: Mumbai
Date: 4th November, 2026

By Order of the Board
For Unichem Laboratories Limited
Pabitrakumar Kalipada Bhattacharyya
Date: 2026.11.04 12:57:48 +05'30'

UNICHEM LABORATORIES LTD. MUMBAI 400 067.

Pabitrakumar Kalipada Bhattacharyya
Managing Director and Chief Executive Officer
DIN: 07131152

UNICHEM

Independent Auditor's Review Report on Quarterly and Half yearly Standalone Unaudited Financial Results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors
Unichem Laboratories Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ("the Statement") of **Unichem Laboratories Limited** ("the Company") for the quarter and half year ended 30th September 2026, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

Management's responsibility

2. The Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

Auditor's responsibility

3. Our responsibility is to issue a report on this Statement based on our review.

   We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Independent Auditor's Review Report on Quarterly and Half yearly Standalone Unaudited Financial Results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (continued)

Conclusion

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of standalone unaudited financial results, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards i.e. 'Ind AS' prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N. A. Shah Associates LLP
Chartered Accountants
Firm's Registration No.: 116560W / W100149

BHAVIN SURENDRA KAPADIA
Digitally signed by BHAVIN SURENDRA KAPADIA
Date: 2026.11.04 13:14:26 +05'30'

Bhavin Kapadia
Partner
Membership No.: 118991
UDIN: 26118991ROBYTE1117

Place: Mumbai
Date: 4th November, 2026